RAND:EURONEXT AMSTERDAMRandstad NV Analysis
Data as of 2026-07-12 - not real-time
$10.20
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Rand Capital trades below its short‑term moving averages (20‑day SMA ≈ 10.26, 50‑day SMA ≈ 10.55) and well under the 200‑day SMA (~12.08), confirming a bearish price bias. The RSI sits near 45, the MACD line has just crossed above its signal, and volume is on a downward trend, all pointing to limited upside momentum and a price range bounded by a support around 10.01 and resistance near 10.49. Low beta (≈ 0.24) and a 30‑day volatility of over 21% suggest the stock moves independently of broader markets but can swing sharply.
Fundamentally, the company reports a sizable net loss (trailing EPS –3.14) and a negative profit margin, yet it distributes an 11% dividend yield funded largely by return of capital. Cash reserves are modest relative to debt, and free cash flow, while positive, is insufficient to comfortably sustain the payout. A discounted cash‑flow model values the shares near $6.8, well below the current $10.2 price, indicating the market may be over‑pricing the stock despite its attractive yield.
Fundamentally, the company reports a sizable net loss (trailing EPS –3.14) and a negative profit margin, yet it distributes an 11% dividend yield funded largely by return of capital. Cash reserves are modest relative to debt, and free cash flow, while positive, is insufficient to comfortably sustain the payout. A discounted cash‑flow model values the shares near $6.8, well below the current $10.2 price, indicating the market may be over‑pricing the stock despite its attractive yield.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Price below key moving averages and near support
- Decreasing volume and bearish technical setup
- Dividend payout likely unsustainable given losses
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- DCF fair value suggests significant downside
- High dividend yield may attract income seekers
- Continued earnings weakness limits upside
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Persistent negative earnings and weak profit margins
- Overvaluation relative to intrinsic value
- Potential capital return pressures on dividend sustainability
Key Metrics & Analysis
Financial Health
Revenue Growth-38.30%
Profit Margin-162.06%
ROE-15.91%
ROA4.96%
Debt/Equity0.98
P/B Ratio0.6
Op. Cash Flow$5.1K
Free Cash Flow$1.6M
Industry P/E17.6
Technical Analysis
TrendBearish
RSI45.5
Support$10.01
Resistance$10.49
MA 20$10.26
MA 50$10.55
MA 200$12.08
MACDBullish
VolumeDecreasing
Fear & Greed Index94.59
Valuation
Fair Value$6.78
GradeOvervalued
TypeValue
Dividend Yield11.26%
Risk Assessment
Beta0.24
Volatility21.33%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.